Innovative clinical trial design for pediatric therapeutics

Matthew M. Laughon, Daniel K. Benjamin, Edmund V. Capparelli, Gregory L. Kearns, Katherine Berezny, Ian Paul, Kelly Wade, Jeff Barrett, Phillip Brian Smith, Michael Cohen-Wolkowiez

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

Until approximately 15 years ago, sponsors rarely included children in the development of therapeutics. US and European legislation has resulted in an increase in the number of pediatric trials and specific label changes and dosing recommendations, although infants remain an understudied group. The lack of clinical trials in children is partly due to specific challenges in conducting trials in this patient population. Therapeutics in special populations, including premature infants, obese children and children receiving extracorporeal life support, are even less studied. National research networks in Europe and the USA are beginning to address some of the gaps in pediatric therapeutics using novel clinical trial designs. Recent innovations in pediatric clinical trial design, including sparse and scavenged sampling, population pharmacokinetic analyses and 'opportunistic' studies, have addressed some of the historical challenges associated with clinical trials in children.

Original languageEnglish (US)
Pages (from-to)643-652
Number of pages10
JournalExpert Review of Clinical Pharmacology
Volume4
Issue number5
DOIs
StatePublished - Sep 1 2011

Fingerprint

Clinical Trials
Pediatrics
Population
Extracorporeal Membrane Oxygenation
Therapeutics
Child Development
Legislation
Premature Infants
Pharmacokinetics
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Laughon, M. M., Benjamin, D. K., Capparelli, E. V., Kearns, G. L., Berezny, K., Paul, I., ... Cohen-Wolkowiez, M. (2011). Innovative clinical trial design for pediatric therapeutics. Expert Review of Clinical Pharmacology, 4(5), 643-652. https://doi.org/10.1586/ecp.11.43
Laughon, Matthew M. ; Benjamin, Daniel K. ; Capparelli, Edmund V. ; Kearns, Gregory L. ; Berezny, Katherine ; Paul, Ian ; Wade, Kelly ; Barrett, Jeff ; Smith, Phillip Brian ; Cohen-Wolkowiez, Michael. / Innovative clinical trial design for pediatric therapeutics. In: Expert Review of Clinical Pharmacology. 2011 ; Vol. 4, No. 5. pp. 643-652.
@article{64ac540f672042158e7aab80fad8b90c,
title = "Innovative clinical trial design for pediatric therapeutics",
abstract = "Until approximately 15 years ago, sponsors rarely included children in the development of therapeutics. US and European legislation has resulted in an increase in the number of pediatric trials and specific label changes and dosing recommendations, although infants remain an understudied group. The lack of clinical trials in children is partly due to specific challenges in conducting trials in this patient population. Therapeutics in special populations, including premature infants, obese children and children receiving extracorporeal life support, are even less studied. National research networks in Europe and the USA are beginning to address some of the gaps in pediatric therapeutics using novel clinical trial designs. Recent innovations in pediatric clinical trial design, including sparse and scavenged sampling, population pharmacokinetic analyses and 'opportunistic' studies, have addressed some of the historical challenges associated with clinical trials in children.",
author = "Laughon, {Matthew M.} and Benjamin, {Daniel K.} and Capparelli, {Edmund V.} and Kearns, {Gregory L.} and Katherine Berezny and Ian Paul and Kelly Wade and Jeff Barrett and Smith, {Phillip Brian} and Michael Cohen-Wolkowiez",
year = "2011",
month = "9",
day = "1",
doi = "10.1586/ecp.11.43",
language = "English (US)",
volume = "4",
pages = "643--652",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "5",

}

Laughon, MM, Benjamin, DK, Capparelli, EV, Kearns, GL, Berezny, K, Paul, I, Wade, K, Barrett, J, Smith, PB & Cohen-Wolkowiez, M 2011, 'Innovative clinical trial design for pediatric therapeutics', Expert Review of Clinical Pharmacology, vol. 4, no. 5, pp. 643-652. https://doi.org/10.1586/ecp.11.43

Innovative clinical trial design for pediatric therapeutics. / Laughon, Matthew M.; Benjamin, Daniel K.; Capparelli, Edmund V.; Kearns, Gregory L.; Berezny, Katherine; Paul, Ian; Wade, Kelly; Barrett, Jeff; Smith, Phillip Brian; Cohen-Wolkowiez, Michael.

In: Expert Review of Clinical Pharmacology, Vol. 4, No. 5, 01.09.2011, p. 643-652.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Innovative clinical trial design for pediatric therapeutics

AU - Laughon, Matthew M.

AU - Benjamin, Daniel K.

AU - Capparelli, Edmund V.

AU - Kearns, Gregory L.

AU - Berezny, Katherine

AU - Paul, Ian

AU - Wade, Kelly

AU - Barrett, Jeff

AU - Smith, Phillip Brian

AU - Cohen-Wolkowiez, Michael

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Until approximately 15 years ago, sponsors rarely included children in the development of therapeutics. US and European legislation has resulted in an increase in the number of pediatric trials and specific label changes and dosing recommendations, although infants remain an understudied group. The lack of clinical trials in children is partly due to specific challenges in conducting trials in this patient population. Therapeutics in special populations, including premature infants, obese children and children receiving extracorporeal life support, are even less studied. National research networks in Europe and the USA are beginning to address some of the gaps in pediatric therapeutics using novel clinical trial designs. Recent innovations in pediatric clinical trial design, including sparse and scavenged sampling, population pharmacokinetic analyses and 'opportunistic' studies, have addressed some of the historical challenges associated with clinical trials in children.

AB - Until approximately 15 years ago, sponsors rarely included children in the development of therapeutics. US and European legislation has resulted in an increase in the number of pediatric trials and specific label changes and dosing recommendations, although infants remain an understudied group. The lack of clinical trials in children is partly due to specific challenges in conducting trials in this patient population. Therapeutics in special populations, including premature infants, obese children and children receiving extracorporeal life support, are even less studied. National research networks in Europe and the USA are beginning to address some of the gaps in pediatric therapeutics using novel clinical trial designs. Recent innovations in pediatric clinical trial design, including sparse and scavenged sampling, population pharmacokinetic analyses and 'opportunistic' studies, have addressed some of the historical challenges associated with clinical trials in children.

UR - http://www.scopus.com/inward/record.url?scp=80052765511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052765511&partnerID=8YFLogxK

U2 - 10.1586/ecp.11.43

DO - 10.1586/ecp.11.43

M3 - Review article

VL - 4

SP - 643

EP - 652

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 5

ER -

Laughon MM, Benjamin DK, Capparelli EV, Kearns GL, Berezny K, Paul I et al. Innovative clinical trial design for pediatric therapeutics. Expert Review of Clinical Pharmacology. 2011 Sep 1;4(5):643-652. https://doi.org/10.1586/ecp.11.43